Archives of Biochemistry and Biophysics, Год журнала: 2025, Номер unknown, С. 110431 - 110431
Опубликована: Апрель 1, 2025
Язык: Английский
Cancer Communications, Год журнала: 2023, Номер 44(1), С. 23 - 46
Опубликована: Ноя. 20, 2023
Abstract Lung cancer is the second most common and deadliest type of worldwide. Clinically, non‐small cell lung (NSCLC) pathological cancer; approximately one‐third affected patients have locally advanced NSCLC (LA‐NSCLC, stage III NSCLC) at diagnosis. Because its heterogeneity, LA‐NSCLC often requires multidisciplinary assessment. Moreover, prognosis much below satisfaction, efficacy traditional therapeutic strategies has reached a plateau. With emergence targeted therapies immunotherapies, as well continuous development novel radiotherapies, we entered an era treatment paradigm for LA‐NSCLC. Here, reviewed landscape relevant modalities, including adjuvant, neoadjuvant, perioperative immune in with resectable with/without oncogenic alterations; combinations chemoradiation immunotherapy/targeted therapy unresectable We addressed unresolved challenges that remain field, examined future directions to optimize clinical management increase cure rate
Язык: Английский
Процитировано
43
Cancer Letters, Год журнала: 2025, Номер 612, С. 217494 - 217494
Опубликована: Янв. 23, 2025
Язык: Английский
Процитировано
2
Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер unknown, С. 104669 - 104669
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
2
Advanced Science, Год журнала: 2025, Номер unknown
Опубликована: Янв. 21, 2025
Abstract Metabolic disorders have been identified as one of the causes drug‐induced liver injury; however, direct regulatory mechanism regarding this disorder has not yet clarified. In study, a single small molecule kinase inhibitors, with crizotinib representative drug is elucidated. First, it discovered that induced aberrant lipid metabolism and apoptosis in liver. A mechanistic study revealed treatment promoted accumulation squalene epoxidase (SQLE) by inhibiting autophagosome‐lysosome fusion which blocked autophagic degradation SQLE. maladaptive increase SQLE led to disturbances cholesterol sphingolipid via an enzymatic activity‐dependent manner. Abnormal results both steatosis inflammatory infiltration, promote cell inducing lysosomal membrane permeabilization. The restoration level or activity ameliorated hepatocyte injury. autophagy activator known metformin inhibitor terbinafine potential clinical use for alleviating hepatotoxicity.
Язык: Английский
Процитировано
1
Cancer Cell International, Год журнала: 2024, Номер 24(1)
Опубликована: Июнь 20, 2024
Non-small cell lung cancer (NSCLC) is a common and aggressive primary malignancy worldwide. Dysregulation of long non-coding RNAs (lncRNAs) has been shown to play an essential regulatory role in multiple cancers. However, the PGM5-AS1 NSCLC remains unclear. Here, we found that was down-regulated tissues cells. Furthermore, reduced expression levels were associated with larger tumor size, positive lymph node metastasis, advanced TNM stage worse prognosis. We overexpression inhibited proliferation induced apoptosis G0/G1 cycle arrest lines. Using dual luciferase gene reporter RNA immunoprecipitation assays, confirmed miR-423-5p interacted PGM5-AS1, their negatively correlated tissues. also reverse PGM5-AS1-induced malignant biological behavior. Moreover, identified slit guidance ligand 2 (SLIT2) as target miR-423-5p. assay, relationship between SLIT2 demonstrated correlated. Our rescue experiments showed knockdown reversed miR-423-5p-mediated effects. Overall, this study identifies potential prognostic biomarker for shows suppresses development by regulating miR-423-5p/SLIT2 axis.
Язык: Английский
Процитировано
5
Journal of Materials Chemistry B, Год журнала: 2024, Номер 12(38), С. 9740 - 9759
Опубликована: Янв. 1, 2024
Inhalable hybrid nano-assemblies incorporating the tumor homing peptide TMTP1 effectively target and kill tumors, offering a promising therapeutic strategy for advanced small cell lung cancer.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Апрель 30, 2024
Objectives Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). However, application ICIs can also cause treatment-related adverse events (trAEs) and immune-related (irAEs). This study was to evaluate both irAEs trAEs different ICI strategies for NSCLC based on randomized clinical trials (RCTs). The examined real-world pharmacovigilance data from Food Drug Administration Adverse Event Reporting System (FAERS) regarding claimed ICI-associated AEs in practice. Methods Based Pubmed, Embase, Medline, Cochrane CENTRAL, we retrieved RCTs comparing with chemotherapy drugs or regimens up October 20, 2023. Bayesian network meta-analysis (NMA) performed using odds ratios (ORs) 95% credible intervals (95%CrI). Separately, a retrospective FAERS database, extracting patients between first quarter (Q1) 2004 Q4 proportional reports reporting ratio calculated analyze disproportionality. Results NMA included 51 that involved total 26,958 NSCLC. lowest risk any trAEs, cemiplimab, tislelizumab, durvalumab were ranked as best. Among agents associated grades 3-5 avelumab, nivolumab most likely rank highest. As far are concerned, atezolizumab plus bevacizumab is considered safety option. it high trAEs. result analysis, 9,420 cases been identified 7,339 treated ICIs, related statistically significant positive signal 311 preferred terms (PTs), comprehensively investigated those highly ICIs. In total, 152 signals Nivolumab, malignant neoplasm progression, death, hypothyroidism being frequent PTs. Conclusion These findings revealed differed their profile. be improved preventive methods developed our results.
Язык: Английский
Процитировано
4
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 4, 2025
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2025, Номер 15
Опубликована: Фев. 3, 2025
Background The coexistence of lung cancer and pulmonary tuberculosis (TB) makes differential diagnosis even more complicated. purpose the study is to explore superiority [ 18 F]-NOTA-FAPI-04 PET/CT in distinguishing TB from malignant lesions accurately detecting inflammatory lymph nodes than F]-FDG PET/CT. Case summary Herein, we described a case report patient with both underwent Al[ positron emission tomography/computed tomography (PET/CT) determine staging. Additionally, literature review was conducted discuss potential clinical applications FAPI We reported 70-year-old man newly diagnosed squamous cell carcinoma avid uptake old right hilar (<1 cm) were not found on Al After 2 months follow-up, small node finally confirmed be inflammatory. Conclusion may perform better malignancy offer greater specificity for nodes.
Язык: Английский
Процитировано
0
BMC Cancer, Год журнала: 2025, Номер 25(1)
Опубликована: Фев. 21, 2025
There is no consensus regarding whether primary tumour resection (PTR) should be performed in non-small cell lung cancer (NSCLC) patients with unexpected pleural dissemination (PD) discovered at thoracotomy. Consecutive NSCLC surgically confirmed PD were retrospectively enrolled from two high-volume centres between January 2016 and December 2023. Patients divided into the exploratory thoracotomy (ET) group. PTR included wedge resection, segmentectomy lobectomy. ET group received biopsy only. Propensity score matching (PSM) was used to reduce selection bias confounding factors. Disease-specific survival (DSS) progression-free (PFS) analysed using Kaplan‒Meier method, comparisons made log-rank test. Multivariate Cox regression analyses identify independent prognostic A total of 223 identified: 167 (74.9%) 56 (25.1%) The median follow-up time (MST) 39.0 months 49.0 months, respectively. MST for groups 44.0 60.0 respectively (HR 0.80, 95% CI 0.51–1.24; p = 0.3097). After PSM, there significant differences terms disease-specific (DSS: vs. 61.0 0.3419) or (PFS: 30.0 47.0 0.5471) groups. analysis revealed that smoking history a size ≥ 3 cm risk factors DSS PFS, whereas targeted therapy an protective factor. Our results suggest does not improve long-term It high re-evaluate value surgery avoid overtreatment, especially era immunotherapy. ClinicalTrials.gov NCT06232967 (approval date: 31, 2024).
Язык: Английский
Процитировано
0